About: The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 07 November 2006

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в листопаді 2006 (uk) im November 2006 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en payares de 2006 (ast) scientific article published on 07 November 2006 (en)
publication date	wds:Q62818294-71D477F3-6C2A-4D77-B4E3-8149829B37D9
publication date	2006-11-07 00:00:00Z (xsd:dateTime)
author name string	wds:Q62818294-35E83121-51A5-4BED-86F4-88B4840E4A4E wds:Q62818294-38689A65-7DE6-4A8A-9969-64F68A52EA27 wds:Q62818294-683BECC2-3450-4DA4-92E0-F73D6E0B05A8 wds:Q62818294-CFB3AFAC-CFB1-432D-A6F6-EDF0AAD3BE9B wds:Q62818294-D21CCB6F-1C6B-4616-A2D2-36A4C878AE0F wds:Q62818294-F503F671-4293-4AB7-A9BA-4BB63C916100
author name string	Thompson S Prince HM Seymour JF Grigg AP Hoyt R Ritchie DS
rdfs:label	The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma (en) The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma (nl)
skos:prefLabel	The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma (en) The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma (nl)
name	The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma (en) The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma (nl)
author	wds:Q62818294-0ACF4995-2B56-4858-AF73-12644FE78621 wds:Q62818294-B6B0FAA6-050D-4F93-B971-B85285861EDF
author	Jeff Szer Andrew W. Roberts
title	wds:Q62818294-F99BA996-4391-4F91-8E5D-EC59A13B7512
title	The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma (en)
page(s)	wds:Q62818294-B2DF3E9E-94A7-430A-A98D-D8906C9D8F2C
page(s)	101-105
instance of	wds:Q62818294-FE881DA7-1ED2-401C-A2F4-78052854DCE9
instance of	scholarly article
main subject	wds:Q62818294-1AEEEAC5-1E6E-4491-81C0-6536BB16F566 wds:Q62818294-C0C4D11A-E11D-44B8-875E-917732B0658F wds:Q62818294-E0EFDFBD-31EB-4C64-B26A-732B8BAAC794
main subject	chemotherapy mantle cell lymphoma stem cell transplantation
PubMed ID	wds:Q62818294-25C206D8-88B4-4A14-BA7B-5364B9267C44
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17089127
PubMed ID	17089127
published in	wds:Q62818294-0987A078-9A71-4BF1-9F8A-1C65C6358EA4
published in	Annals of Hematology
issue	wds:Q62818294-42052187-48D4-465D-B5D7-BAAA472301B6
volume	wds:Q62818294-B743E3DA-E583-4210-A88B-D86165F1E5DB
issue	2
volume	86
DOI	wds:Q62818294-485EAE5F-AED3-4427-A30B-2D0D8337CCDF
DOI	http://dx.doi.org/10.1007/S00277-006-0193-2
DOI	10.1007/S00277-006-0193-2
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q62818294
is cites work of	Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study Non-Hodgkin's lymphomas, version 4.2014. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Mantle cell lymphoma: evolving novel options Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cyta Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma Immunophenotypic profile and clinical characteristics in patients with advanced stage mantle cell lymphoma A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma Endoscopic features and prognoses of mantle cell lymphoma with gastrointestinal involvement Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen Combined systemic and ocular chemotherapy for anterior segment metastasis of systemic mantle cell lymphoma Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma Authors' reply
is cites work of	wds:Q36913251-E4AA11EF-BC40-4815-BDB8-BFE061B1043C wds:Q93082193-D7449F33-A784-4DD9-8FC2-4B0AFB05DBE4 wds:Q34603567-FA7984A6-2B79-4FFB-A0E0-6B262E30DD77 wds:Q81631158-355B3814-4A43-424A-83D8-5CA170142991 wds:Q41097746-A1405CBA-51CE-4381-94C4-C2ACCD6F6262 wds:Q36837797-C16510C1-11E4-4580-BC89-F0ADB2790F9D wds:Q38552083-B85FB2F2-2706-47E3-A93C-288BE3A9107F wds:Q46146766-70629C88-CD2E-4746-BEE8-EF2CB2B4C86B wds:Q58615647-0888C080-E7D0-439C-B851-FC42443BD8A2 wds:Q93819069-70229994-DDAA-42F7-83C3-DADF03DB96D0 wds:Q36301583-F0FF592C-7428-411F-A860-7C52CB27D657 wds:Q30358639-9829B9D6-624E-4A28-9DC6-888E19C406C2 wds:Q33572807-30BA24DB-6EF1-4F7F-8091-C9FE959FF07D wds:Q81399032-10AF1FDC-D8A6-4CFD-8B0B-6562F0BC0406 wds:Q28075606-71AA1C98-4DAC-44D7-8090-1F6AF3387562 wds:Q36820885-9EB9766A-3F85-4651-B37B-2FF5BFCD2153 wds:Q33586239-7C459520-8407-42A3-9B93-A9FFEE512DDA wds:Q34183167-5A408F47-231C-42A1-9950-1BFB164C0941 wds:Q34095473-3D4E8D12-9A42-4FAE-83FC-73CDED1CD80C wds:Q37402853-A3FD9F55-2563-46AC-AC03-8CE17337F350

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software